American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 197-207 , February 2009

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis

  • Michel Chonchol, MD

      Affiliations

    • University of Colorado Health Science Center, Denver, CO
    • Corresponding Author InformationAddress correspondence to Michel Chonchol, MD, Associate Professor, University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension, 4200 E. 9th Ave, Box C-281, Denver, CO 80262
    • ,
  • Francesco Locatelli, MD

      Affiliations

    • Azienda Ospedaliera di Lecco, Nephrology, Lecco, Italy
    • ,
  • Hanna E. Abboud, MD

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX
    • ,
  • Chaim Charytan, MD

      Affiliations

    • NY Hospital Medical Center of Queens, Flushing, NY
    • ,
  • Angel L.M. de Francisco, MD

      Affiliations

    • Hospital Margues de Valdecilla, Santander, Spain
    • ,
  • Shivinder Jolly, MD

      Affiliations

    • Clinical Research Solutions, Kitchener, Ontario, Canada
    • ,
  • Mark Kaplan, MD

      Affiliations

    • Nephrology Associates, Nashville, TN
    • ,
  • Simon D. Roger, MD

      Affiliations

    • Northern Sydney Central Coast Health, Gosford, NSW, Australia
    • ,
  • Shyamal Sarkar, MD

      Affiliations

    • Advanced Kidney Specialists, Jackson, TN
    • ,
  • Moetaz B. Albizem, MD

      Affiliations

    • Amgen Inc, Thousand Oaks, CA
    • ,
  • T. Christian H. Mix, MD

      Affiliations

    • Amgen Inc, Thousand Oaks, CA
    • ,
  • Yumi Kubo, MS

      Affiliations

    • Amgen Inc, Thousand Oaks, CA
    • ,
  • Geoffrey A. Block, MD

      Affiliations

    • Denver Nephrology PC, Denver, CO

Received 13 February 2008 ,Accepted 9 September 2008.

References 

  1. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol. 2005;288:F253–F264
  2. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496–502
  3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38
  4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  5. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(suppl 2):S34–S38
  6. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187
  7. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  8. Verberckmoes SC, Persy V, Behets GJ, et al. Uremia-related vascular calcification: More than apatite deposition. Kidney Int. 2007;71:298–303
  9. Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9:517–523
  10. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002;17:2094–2105
  11. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18:1159–1166
  12. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47:1434–1442
  13. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358–363
  14. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580
  15. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: Correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol. 2006;17:107–112
  16. Ramirez JA, Goodman WG, Gornbein J, et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab. 1993;76:1489–1494
  17. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308:627–635
  18. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  19. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807
  20. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58–67
  21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  22. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135–141
  23. Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphorus. Clin J Am Soc Nephrol. 2006;1:305–312
  24. Bindels RJ. Calcium handling by the mammalian kidney. J Exp Biol. 1993;184:89–104
  25. Satomura K, Seino Y, Yamaoka K, et al. Renal 25-hydroxyvitamin D3-1-hydroxylase in patients with renal disease. Kidney Int. 1988;34:712–716
  26. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865
  27. Tenenhouse HS. Regulation of phosphorus homeostasis by the type IIa Na/phosphate cotransporter. Annu Rev Nutr. 2005;25:197–214
  28. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol. 1999;277:F157–F175
  29. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology. 1998;139:4391–4396
  30. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S201
  31. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–528
  32. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007;71:134–139
  33. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026–1033
  34. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–894
  35. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50:59–68
  36. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27:36–43
  37. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol. 2005;16:1788–1793
  38. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800
  39. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  40. Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant. 1996;11:813–819
  41. Shoji T, Emoto M, Tabata T, et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002;61:2187–2192
  42. Spiegel D, Raggi P, Mehta R, et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int. 2004;8:265–272
  43. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56:1084–1093
  44. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825–831
  45. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007;2:89–99
  46. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467–476
  47. Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006;17:795–804
  48. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–276
  49. Abboud H, Coyne D, Smolenski O, et al. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol. 2006;26:105–114
  50. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43:877–890

 A list of author affiliations appears at the end of this article.

 Trial registration: http://clinicaltrials.gov; study number: NCT00094484.

 Originally published online as doi:10.1053/j.ajkd.2008.09.021 on December 25, 2008.

PII: S0272-6386(08)01569-2

doi: 10.1053/j.ajkd.2008.09.021

American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 197-207 , February 2009

Article Tools

* Image Usage & Resolution